Results 101 to 110 of about 101,548 (353)

A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS

Women's Health
Polycystic ovary syndrome is a common reproductive endocrine condition that affects women of fertile age and is characterized by three main features, including hyperandrogenism, chronic anovulation, and polycystic ovaries. In addition, half of women with
Salwa Bader, Rahila Bhatti, Bashair Mussa, Salah Abusanana   +3 more
doaj   +1 more source

Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways [PDF]

, 2016
Glucagon-like peptide-1 (GLP-1), a metabolic signal molecule, regulates reproduction, although, the involved molecular mechanisms have not been elucidated, yet.
Csaba Fekete, Csaba Vastagh, Erik Hrabovszky, Erzsébet Farkas, Flóra Bálint, Imre Farkas, Katalin Skrapits, Zsolt Liposits   +7 more
core   +1 more source

A phase 3 randomized clinical trial using a once‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity

Diabetes, obesity and metabolism, 2020
To evaluate the efficacy, safety and tolerability of a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in patients with hypothalamic obesity (HO).
Christian L. Roth, Francisco A. Perez, Kathryn B. Whitlock, Clinton T. Elfers, J. Yanovski, A. Shoemaker, M. J. Abuzzahab   +6 more
semanticscholar   +1 more source

Small-molecule agonists for the glucagon-like peptide 1 receptor [PDF]

Proceedings of the National Academy of Sciences, 2007
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes. As a peptide hormone, GLP-1 has to be administered by injection. Only a few small-molecule agonists to peptide hormone receptors have been described and none in the B family of the G protein ...
Knudsen, Lotte Bjerre, Kiel, Dan, Teng, Min, Behrens, Carsten, Bhumralkar, Dilip, Kodra, János T, Holst, Jens Juul, Jeppesen, Claus B, Johnson, Michael D, de Jong, Johannes Cornelis, Jorgensen, Anker Steen, Kercher, Tim, Kostrowicki, Jarek, Madsen, Peter, Olesen, Preben H, Petersen, Jacob S, Poulsen, Fritz, Sidelmann, Ulla G, Sturis, Jeppe, Truesdale, Larry, May, John, Lau, Jesper   +21 more
openaire   +3 more sources

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis

International Journal of Molecular Sciences, 2020
Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat diabetes, but their effects on nonalcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) remain unclear. In this study, mice with streptozotocin- and high-
Motoyasu Kojima, Hirokazu Takahashi, T. Kuwashiro, Kenichi Tanaka, Hitoe Mori, I. Ozaki, Yoichiro Kitajima, Y. Matsuda, Kenji Ashida, Yuichiro Eguchi, K. Anzai   +10 more
semanticscholar   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Nature Communications
Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy ...
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman   +11 more
doaj   +1 more source

Review article: a comparison of glucagon-like peptides 1 and 2. [PDF]

, 2013
BACKGROUND: Recent advancements in understanding the roles and functions of glucagon-like peptide 1 (GLP-1) and 2 (GLP-2) have provided a basis for targeting these peptides in therapeutic strategies.
Amato, Amato, Amato, Amin, Andrews, Andrews, Angelone, Anini, Anvari, Au, Baggio, Baggio, Bahrami, Baldassano, Baldassano, Bengi, Benjamin, Bjerknes, Blomgren, Booth, Bose, Boushey, Boushey, Bremholm, Brubaker, Brubaker, Brubaker, Brubaker, Buchman, Bucinskaite, Bullock, Buse, Caddy, Cameron, Cameron, Campos, Cani, Chance, Cheeseman, Cinci, Cummings, Daniel, Deacon, Deacon, Delgado-Aros, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Dube, Dube, Dube, Dunphy, Estall, Farilla, Fehmann, Flint, Garber, Giralt, Goke, Guan, Guan, Gutzwiller, Gutzwiller, Hadjiyanni, Hansen, Hansen, Hargrove, Hartmann, Herrmann, Holst, Holst, Hornby, Hsieh, Hui, Iakoubov, Imeryuz, Iwai, Jeppesen, Jeppesen, Jeppesen, Jeppesen, Jeppesen, Johansen, Kato, Kendall, Kieffer, Kim, Kim, Knauf, Knudsen, Koehler, Koehler, Koopmann, Koopmann, Kunkel, Leen, Li, Lim, Linnebjerg, Liu, Liu, Lovshin, Lovshin, Lovshin, Madsbad, Marre, Martin, Martin, McDonagh, Meier, Meier, Miki, Moretto, Munroe, Nagell, Nakagawa, Naslund, Naslund, Nauck, Nelson, Nelson, Nielsen, Nikolaidis, Nystrom, Orskov, Orskov, Orskov, Orskov, Orskov, Orskov, Parks, Peters, Petersen, Petersen, Petersen, Pinelli, Portha, Reimann, Reimann, Roberge, Rocca, Rotondo, Rouille, Rowland, Rowland, Ruiz-Grande, Schirra, Schmidt, Schmidt, Schwartz, Scott, Shin, Sigalet, Sigalet, Sinclair, Skarbaliene, Sorensen, Stephens, Sturis, Tanaka, Tang-Christensen, Tang-Christensen, Tavares, Tee, Thong, Thulesen, Thulesen, Tolessa, Tolessa, Tornehave, Trivedi, Tsai, Tsai, Ugleholdt, Velazquez, Velazquez, Verdich, Voss, Vrang, Wallis, Wallis, Washizawa, Wettergren, Wettergren, Wheeler, Wideman, Wishart, Wojdemann, Wojdemann, Xiao, Xiao, Xu, Yamamoto, Yamazaki, Yusta, Yusta, Zhu, Zinman   +202 more
core   +1 more source

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Diabetes Therapy, 2020
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration.
S. Kalra, R. Sahay
semanticscholar   +1 more source